Home RxNorm 2055664 antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection [Jivi] Drug identity information. FDA.report links public drug records from RxNav, DailyMed, FDA NDC, Drugs@FDA, and related public sources where available. This page is informational only and is not medical, prescribing, or regulatory advice.
RxCUI 2055664
RxNorm name antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection [Jivi]
Display name antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection [Jivi]
Full name antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection [Jivi]
Term type SBD
Status DailyMed mapping
Updated 2026-06-04 23:39:27 Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 125661 Jivi Antihemophilic factor (recombinant), PEGylated-aucl 351(a) Rx 2026-08-01
RxNav Current And Historical NDCs# RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.
No records found.
UNII Substances# UNII substance links page 1 of 1 · 0 matching rows.
No records found.
DailyMed RxNorm Mappings# unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.
Set ID, RxNorm mappings, Terms table Set ID RxNorm mappings Terms SPL version Label Effective f04e5bd5-d7e2-453b-a407-2616d81a695d Jivi 1 UNT Injection [PSN] · antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection [Jivi] [SBD] · Jivi 1 UNT Injection [SY] 3 13 These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018 20260302